ID: h-SDA-2026-04-26-gap-20260426-001521-05-
Hypothesis
Circulating Endothelial Microparticles Expressing Activated LRP1 and CD31 Identify Pre-Symptomatic Neurodegeneration
Cerebral microvascular endothelial cells shed submicron microparticles (EMPs) upon activation or apoptosis.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Cerebral microvascular endothelial cells shed submicron microparticles (EMPs) upon activation or apoptosis. EMPs carry surface markers reflecting parent cell state—CD31, CD105, and LRP1. Analyzing circulating EMP populations via flow cytometry provides a real-time snapshot of cerebral endothelial status. However, flow cytometry standardization across laboratories is lacking, and pre-analytical variables dramatically affect EMP counts.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["PECAM1<br/>Platelet Endothelial Cell Adhesion"]
B["Endothelial<br/>Microparticles"]
C["Circulating EMPs<br/>CD31+/CD144+"]
D["Vascular<br/>Endothelial Activation"]
E["BBB<br/>Dysfunction"]
F["Prothrombotic<br/>State"]
G["Neurovascular<br/>Compromise"]
H["Cognitive<br/>Impairment"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
Reduced neuronal-derived and endothelial-derived exosome LRP1 in AD patients years before symptom onset
Supports
Plasma endothelial microparticle profiles distinguish AD from controls with high sensitivity
Supports
EMP CD31/CD42 ratio correlates with BBB permeability MRI metrics in vascular cognitive impairment
Contradicts
No standardized flow cytometry protocol for EMP analysis across laboratories
Contradicts
Pre-analytical variables (blood collection time, anticoagulant, processing delay) dramatically affect EMP counts
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PECAM1
No curated PDB or AlphaFold mapping for PECAM1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for PECAM1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PECAM1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0563
Events (7d)
1
Price History
▼2.3%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we compare circulating EMP phenotypes (activated LRP1+/CD31+ EMP count per μL plasma) between cognitively normal individuals at genetic risk for neurodegeneration (APOE4 homozygous, n≥50) and age-m | Activated LRP1+/CD31+ EMP count significantly higher in neurodegeneration-risk group vs. non-neurodegenerative inflammation group. | — no observation — | pending | 0.65 |
| IF we stratify cognitively normal adults aged 60-80 years into quartiles based on baseline circulating activated LRP1+/CD31+ EMP count (standardized flow cytometry), THEN the highest quartile (Q4) wil | MCI/dementia incidence in Q4 ≥15% vs. Q1 ≤7.5% within 3 years. | — no observation — | pending | 0.58 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we compare circulating EMP phenotypes (activated LRP1+/CD31+ EMP count per μL plasma) between cognitively normal individuals at genetic risk for neurodegeneration (APOE4 homozygous, n≥50) and age-matched patients with active non-neurodegenerative inflammatory disease (e.g., rheumatoid arthritis f
Predicted outcome: Activated LRP1+/CD31+ EMP count significantly higher in neurodegeneration-risk group vs. non-neurodegenerative inflammation group.
Falsification: No significant difference in activated LRP1+/CD31+ EMP count between groups (p≥0.05) OR inflammatory disease group shows equal/higher EMP levels, indicating EMP elevation is non-specific.
pendingconf 58%
IF we stratify cognitively normal adults aged 60-80 years into quartiles based on baseline circulating activated LRP1+/CD31+ EMP count (standardized flow cytometry), THEN the highest quartile (Q4) will demonstrate ≥2-fold increased incidence of MCI or dementia diagnosis within 36 months compared to
Predicted outcome: MCI/dementia incidence in Q4 ≥15% vs. Q1 ≤7.5% within 3 years.
Falsification: Incidence in Q4 not significantly different from Q1 (relative risk <1.5, p≥0.05) OR Q1 shows equal/higher progression rate, disproving EMP count as a predictive biomarker.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.